Raquel Gonzalez and colleagues highlight an urgent need to evaluate antimalarials that can be safely administered to HIV-infected pregnant women on antiretroviral treatment and cotrimoxazole prophylaxis. African HIV-infected pregnant women are the most vulnerable population group to malaria infection. • Paradoxically, these women are also the least protected against malaria due to fear of potential interactions between antiretroviral and antimalarial drugs. • Action is urgently needed to evaluate antimalarials that can be safely administered to HIV-infected pregnant women on antiretroviral treatment and cotrimoxazole prophylaxis.